236 related articles for article (PubMed ID: 22585575)
1. CHK1 targets spleen tyrosine kinase (L) for proteolysis in hepatocellular carcinoma.
Hong J; Hu K; Yuan Y; Sang Y; Bu Q; Chen G; Yang L; Li B; Huang P; Chen D; Liang Y; Zhang R; Pan J; Zeng YX; Kang T
J Clin Invest; 2012 Jun; 122(6):2165-75. PubMed ID: 22585575
[TBL] [Abstract][Full Text] [Related]
2. Expression of variant isoforms of the tyrosine kinase SYK determines the prognosis of hepatocellular carcinoma.
Hong J; Yuan Y; Wang J; Liao Y; Zou R; Zhu C; Li B; Liang Y; Huang P; Wang Z; Lin W; Zeng Y; Dai JL; Chung RT
Cancer Res; 2014 Mar; 74(6):1845-56. PubMed ID: 24477596
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of spleen tyrosine kinase in hepatocellular carcinoma by promoter CpG island hypermethylation and its potential role in carcinogenesis.
Shin SH; Lee KH; Kim BH; Lee S; Lee HS; Jang JJ; Kang GH
Lab Invest; 2014 Dec; 94(12):1396-405. PubMed ID: 25310533
[TBL] [Abstract][Full Text] [Related]
4. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma.
Yuan Y; Wang J; Li J; Wang L; Li M; Yang Z; Zhang C; Dai JL
Clin Cancer Res; 2006 Nov; 12(22):6687-95. PubMed ID: 17121887
[TBL] [Abstract][Full Text] [Related]
5. UBE2T-regulated H2AX monoubiquitination induces hepatocellular carcinoma radioresistance by facilitating CHK1 activation.
Sun J; Zhu Z; Li W; Shen M; Cao C; Sun Q; Guo Z; Liu L; Wu D
J Exp Clin Cancer Res; 2020 Oct; 39(1):222. PubMed ID: 33087136
[TBL] [Abstract][Full Text] [Related]
6. Mus81 knockdown improves chemosensitivity of hepatocellular carcinoma cells by inducing S-phase arrest and promoting apoptosis through CHK1 pathway.
Wu F; Chen WJ; Yan L; Tan GQ; Li WT; Zhu XJ; Ge XC; Liu JW; Wang BL
Cancer Med; 2016 Feb; 5(2):370-85. PubMed ID: 26714930
[TBL] [Abstract][Full Text] [Related]
7. Vaccinia-related kinase 1 promotes hepatocellular carcinoma by controlling the levels of cell cycle regulators associated with G1/S transition.
Lee N; Kwon JH; Kim YB; Kim SH; Park SJ; Xu W; Jung HY; Kim KT; Wang HJ; Choi KY
Oncotarget; 2015 Oct; 6(30):30130-48. PubMed ID: 26375549
[TBL] [Abstract][Full Text] [Related]
8. Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells.
Takagaki K; Katsuma S; Kaminishi Y; Horio T; Tanaka T; Ohgi T; Yano J
Genes Cells; 2005 Feb; 10(2):97-106. PubMed ID: 15676021
[TBL] [Abstract][Full Text] [Related]
9. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.
Buchner M; Fuchs S; Prinz G; Pfeifer D; Bartholomé K; Burger M; Chevalier N; Vallat L; Timmer J; Gribben JG; Jumaa H; Veelken H; Dierks C; Zirlik K
Cancer Res; 2009 Jul; 69(13):5424-32. PubMed ID: 19549911
[TBL] [Abstract][Full Text] [Related]
10. TRIM59 promotes tumor growth in hepatocellular carcinoma and regulates the cell cycle by degradation of protein phosphatase 1B.
Ying H; Ji L; Xu Z; Fan X; Tong Y; Liu H; Zhao J; Cai X
Cancer Lett; 2020 Mar; 473():13-24. PubMed ID: 31875525
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma.
Liu Y; Sun L; Su X; Guo S
Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474
[TBL] [Abstract][Full Text] [Related]
12. Chk1 inhibition and Wee1 inhibition combine synergistically to impede cellular proliferation.
Davies KD; Cable PL; Garrus JE; Sullivan FX; von Carlowitz I; Huerou YL; Wallace E; Woessner RD; Gross S
Cancer Biol Ther; 2011 Nov; 12(9):788-96. PubMed ID: 21892012
[TBL] [Abstract][Full Text] [Related]
13. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo.
Feng Z; Xu S; Liu M; Zeng YX; Kang T
Cancer Lett; 2010 Nov; 297(2):190-7. PubMed ID: 20619533
[TBL] [Abstract][Full Text] [Related]
14. Full-length spleen tyrosine kinase inhibits the invasion and metastasis of human laryngeal squamous cell carcinoma.
Li Z; Cai Z; Tao B; Jin Q
Int J Clin Exp Pathol; 2015; 8(12):15786-93. PubMed ID: 26884848
[TBL] [Abstract][Full Text] [Related]
15. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
[TBL] [Abstract][Full Text] [Related]
16. The adaptor molecule CIN85 regulates Syk tyrosine kinase level by activating the ubiquitin-proteasome degradation pathway.
Peruzzi G; Molfetta R; Gasparrini F; Vian L; Morrone S; Piccoli M; Frati L; Santoni A; Paolini R
J Immunol; 2007 Aug; 179(4):2089-96. PubMed ID: 17675467
[TBL] [Abstract][Full Text] [Related]
17. Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma.
Chilà R; Basana A; Lupi M; Guffanti F; Gaudio E; Rinaldi A; Cascione L; Restelli V; Tarantelli C; Bertoni F; Damia G; Carrassa L
Oncotarget; 2015 Feb; 6(5):3394-408. PubMed ID: 25428911
[TBL] [Abstract][Full Text] [Related]
18. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of PSMD4 blocks the tumorigenesis of hepatocellular carcinoma.
Cai MJ; Cui Y; Fang M; Wang Q; Zhang AJ; Kuai JH; Pang F; Cui XD
Gene; 2019 Jun; 702():66-74. PubMed ID: 30930224
[TBL] [Abstract][Full Text] [Related]
20. Involvement of ATM-mediated Chk1/2 and JNK kinase signaling activation in HKH40A-induced cell growth inhibition.
Wang Z; Wang M; Kar S; Carr BI
J Cell Physiol; 2009 Oct; 221(1):213-20. PubMed ID: 19530246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
